In a study of 55 ROS1-positive NSCLC patients (47 post-crizotinib, 32 post-lorlatinib), Lin et al. identified G2032R as the most frequent solvent-front mutation, occurring in 41% and 32% of cases, respectively. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.